国新健康：预计2025年全年扣非后净利润亏损约1.48亿元

Core Viewpoint - Guoxin Health is expected to report a net profit loss of approximately 148 million RMB for the year 2025 after deducting non-recurring gains and losses, primarily due to impairment losses on financial assets [1] Group 1: Financial Performance - For the year 2025, the company achieved an operating income of approximately 351 million RMB, which is roughly the same as the previous year [1] - The net profit attributable to shareholders of the listed company is approximately -409 million RMB [1] - In the first three quarters of 2025, the company's main revenue was 170 million RMB, a year-on-year decrease of 14.87% [2] - The net profit attributable to shareholders for the same period was -138 million RMB, a year-on-year decrease of 347.32% [2] - The third quarter of 2025 saw a single-quarter main revenue of 74.87 million RMB, a year-on-year increase of 19.26% [2] - The single-quarter net profit attributable to shareholders was -39.34 million RMB, a year-on-year decrease of 193.59% [2] - The company reported a gross margin of -5.15% [2] Group 2: Strategic Focus - The company is aligning its operations with the "Healthy China" initiative and the "Three Medical Collaborations" reform, focusing on healthcare industry informationization, digitalization, and intelligence [1] - The strategic focus includes comprehensive management services for medical insurance funds, medical quality and safety services, drug and device regulation, and health service innovation [1] - The company aims to leverage health big data to provide technical support and professional services for the national strategy of "Healthy China" [1] Group 3: Asset Impairment - The increase in losses is mainly attributed to expected impairment of trading financial assets, specifically a 99.01% partnership interest in Shenzhou Borui (Shenzhen) Investment Enterprise [1] - The impairment is linked to a 7.66% stake in Shenzhou Medical Technology Co., Ltd., which is expected to experience a decline in operating performance and lower-than-expected main business income [1] - The company anticipates a fair value change loss of approximately 260 million RMB related to these trading financial assets [1]